NCT01090921 · REGISTRY CONDITION SEARCH

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2020-09-09

This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete Resonse)

→

outcome · POSTED

Number of Participants With Dose Reductions in Bortezomib, Dexamethasone or Both

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Diagnosis of multiple myeloma based on standard criteria. 2. Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of \> 1Gm/dL and/or urine monoclonal immunoglobulin spike of \> 200mg/24 hours. 3. Non-secretors must have measurable protein by Freelite or measurable disease such as plasmacytoma to be eligible. 4. Patient must not have been previously treated with chemotherapy. Prior treatment of hypercalcemia with corticosteroids, or bisphosphonates does not disqualify the patient. 5. Patient must be ineligible for autologous stem cell transplant due to one or more of the following reasons: * Age\>65 * Impaired renal function (creatinine≥2.0 mg/dL) * Impaired pulmonary function (DLCO≤50%) * Poor performance status (KPS≤80) * Other prohibitive comorbid disorder * 5b. Patients≥60 who decline autologous stem cell transplant are eligible for this study. * 5c. Patients who are eligible but wish to postpone autologous stem cell transplant are eligible for this study. 6. Karnofsky performance status\>50 7. Patients treated with local radiotherapy with or without a brief exposure to steroids are eligible. Patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed, followed by a four week wash out period Spot RT to ≤3 vertebrae acceptable prior to entry. 8. Meets the following pretreatment laboratory criteria at Baseline (Within 14 days prior to study drug administration): 1. Platelet count\>50x10\^9/L or, if the bone marrow is extensively infiltrated,\>30x10\^9/L 2. Hemoglobin\>8.0G/dL 3. Absolute neutrophil count \>1.0x10\^9/L or, if the bone marrow is extensively infiltrated, \>0.5x10\^9/L 9. Meets the following pretreatment laboratory criteria for liver function tests at the screening visit conducted within 14 days of registration 1. AST (SGOT): \<3 times the upper limit of institutional laboratory normal 2. ALT (SGPT): \<3 times the upper limit of institutional laboratory normal 3. Total bilirubin: \<2 times the upper limit of institutional laboratory normal, unless clearly related to the disease 10. Women with child-bearing potential should be practicing an adequate form of contraception, as judged by the investigator (i.e. birth control pills, double barrier method, abstinence, etc.) or be surgically sterile or 12 months post-menopausal. Male subject agrees to use an acceptable method for contraception for the duration of the study. 11. Age 18 years or older 12. Has given voluntary written informed consent. Exclusion Criteria: 1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) 2. Plasma cell leukemia 3. Impaired kidney function requiring dialysis, patients on hemodialysis are excluded 4. Receiving steroids \>the equivalent of 10mg prednisone daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis 5. Infection not controlled by antibiotics 6. HIV infection. Patients should provide consent for HIV testing according to the institution's standard practice 7. Known active hepatitis B or C 8. Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities 9. Second malignancy requiring concurrent treatment 10. Other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol 11. Positive pregnancy test in women of childbearing potential 12. Patient has hypersensitivity to boron or mannitol. 13. Patient has ≥Grade 2 peripheral neuropathy within 14 days before enrollment. 14. Patient has received other investigational drugs with 14 days before enrollment
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
intervention Names
Drug: Bortezomib
label
Single-Arm
type
EXPERIMENTAL

interventions

arm Group Labels
Single-Arm
description
Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone.
name
Bortezomib
other Names
Velcade
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 50
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
To evaluate the response rate for weekly administered bortezomib + dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for transplant or who are eligible but wish to postpone autologous stem cell transplant.
measure
Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete Resonse)
time Frame
Data was collected for each subject for the duration of the participation in the study, which was an average of 4.8 cycles.

secondary Outcomes

description
To evaluate the toxicity (safety and tolerability) of weekly bortezomib + dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for transplant or who are eligible but wish to postpone autologous stem cell transplant.
measure
Number of Participants With Dose Reductions in Bortezomib, Dexamethasone or Both
time Frame
Data was collected for each subject for the duration of the participation in the study, which was an average of 4.8 cycles.

Full study description

brief Summary: This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.
detailed Description: This study is a multi-site study which will enroll up to 50 patients with multiple myeloma who have not had prior treatment. Prior to starting treatment individuals will be evaluated to determine if they are eligible to participate in the study. There are certain prestudy test that are required: physical exam, blood tests, ECG, chest x-ray, skeletal survey, bone marrow aspirate and biopsy to confirm the diagnosis of multiple myeloma and to determine baseline health status. Before beginning each treatment cycle and at the end of the study, patients will have protein studies (including blood and urine) to see if they are responding to the treatment. Before each weekly treatment cycle patients will also have blood tests for red and white blood cells and platelets, and blood chemistry tests for electrolytes, kidney and liver function, calcium and blood sugar. Patients may receive up to 6 cycles of treatment. At the end of the study, individuals who have responded to treatment will be seen every two months to check for disease progression.

Source references

references

citation
Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr;169(1):36-43. doi: 10.1111/bjh.13243. Epub 2015 Jan 8.
pmid
25572917
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d69ffe62f21a56e21060
requested nct id
NCT01090921
primary nct id
NCT01090921
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
8ec518849361aff436f9f5cf1c0167df29b77309040f623c2fca2242d6191056
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d69ffe62f21a56e21060
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01090921
occurrences
context exact
NCT01090921
end
11
exact text
NCT01090921
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/857/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
41f499e833572e10d63166cf736367b27d786b00d8e6ecda193a52d6d213d102
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice